Drugs / Seasonal Inactivated Influenza Vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT05310084 | Apr → Oct 2022 | COVID-19 | BioNTech SE | Completed | No outcome recorded |
| Phase 3 | NCT05301322 | Apr → Oct 2022 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01978262 | Oct 2013 → Aug 2017 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02124161 Background | Sep 2014 → May 2015 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seasonal Inactivated Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02124161 ↗ |
| Known as | SIIV | “seasonal inactivated influenza vaccine (SIIV)” NCT05310084 ↗1“seasonal inactivated influenza vaccine (SIIV)” PMID 37992000 ↗ May 2024 |
| Modality | Vaccine | “seasonal inactivated influenza vaccine” NCT01978262 ↗ |
| Route | Intramuscular | “0.5 mL intramuscularly” NCT01978262 ↗ |